Neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A model for parkinson's disease and its therapy
✍ Scribed by Dr. F. V. DeFeudis
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 926 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Monoamine oxidase B metabolizes 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP; **1**) first to 1‐methyl‐4‐phenyl‐2,3‐dihydropyridinium salt (MPDP^+^; **5**), and then to 1‐methyl‐4‐phenylphridinium salt (MPP^+^; **7**). Chemical synthesis of MPDP^+^ and its 5‐methyl analog **6** wa
Primary cultures of mouse astrocytes were treated with both the monoamine oxidase (MAO) A inhibitor, clorgyline, and the MA0 B inhibitor, deprenyl, prior to the addition of the neurotoxicant 1 -methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP). Production of the 1-methyl-4-phenylpyridinium (MPP+) to
Central to the neural mechanism of MPTP-induced parkinsonism is overactivity of the subthalamic nucleus. Lesion of the subthalamic nucleus has therefore been performed in two primates with this condition and found to produce a remarkable amelioration of the disorder.